Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation
AssigneeDyax Corp.
InventorsDaniel J. Sexton, Ryan Faucette
Life of this patent
Estimating the term…
Abstract
Disclosed herein are evacuated blood collection tubes comprising protease inhibitor cocktails in liquid form and uses thereof for assessing features associated with the contact system in a subject, including the endogenous level of contact system activation, the endogenous level of a drug that targets a component of contact system during treatment, and/or the immunogenicity of such a drug.
Claims20
A method for assessing the endogenous level of contact system activation in a subject, the method comprising:
- (i) collecting blood from a subject to an evacuated blood collection tube;
- (ii) processing the blood to produce a plasma sample;
- and
- (iii) measuring the level of contact system activation in the plasma sample,
- wherein the evacuated blood collection tube comprises a liquid formulation that comprises a mixture of protease inhibitors, polybrene, and EDTA, wherein the mixture of protease inhibitors comprises benzamidine, soybean trypsin inhibitor, leupeptin, and 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF).
A method for assessing the level of a drug targeting the contact system in a subject, the method comprising:
- (i) collecting blood from a subject to an evacuated blood collection tube;
- wherein the subject has been administered a drug that targets a component of the contact system;
- (ii) processing the blood to produce a plasma sample;
- and
- (iii) measuring the level of the drug in the plasma sample,
- wherein the evacuated blood collection tube comprises a liquid formulation that comprises a mixture of protease inhibitors, polybrene, and EDTA, wherein the mixture of protease inhibitors comprises benzamidine, soybean trypsin inhibitor, leupeptin, and 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF).
A method for assessing immunogenicity of a drug targeting the contact system, the method comprising:
- (i) collecting blood from a subject to an evacuated blood collection tube;
- wherein the subject has been administered a drug that targets a component of the contact system;
- (ii) processing the blood to produce a plasma sample;
- and
- (iii) measuring the level of antibodies that bind to the drug in the plasma sample,
- wherein the evacuated blood collection tube comprises a liquid formulation that comprises a mixture of protease inhibitors, polybrene, and EDTA, wherein the mixture of protease inhibitors comprises benzamidine, soybean trypsin inhibitor, leupeptin, and 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF).
Dependencies are inferred from the claim text.